The Power of Prevention: Detecting Diabetes Before It Strikes
Rhea-AI Summary
QuidelOrtho (Nasdaq: QDEL) released Episode 53 of its Science Bytes podcast on Nov 20, 2025, featuring Dr. Qian Ding discussing early detection of diabetes.
Key points: early testing can change patient trajectories; emerging biomarkers (C-peptide, pro‑insulin, adiponectin) add metabolic insight beyond glucose; automation-ready lab platforms speed reliable results; early detection supports value-based care and may reduce costly interventions; tailored testing promotes equity across populations. The episode is available on major streaming platforms and at the company website.
Positive
- None.
Negative
- None.
News Market Reaction – QDEL
On the day this news was published, QDEL gained 1.52%, reflecting a mild positive market reaction. Argus tracked a peak move of +10.0% during that session. Our momentum scanner triggered 72 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $25M to the company's valuation, bringing the market cap to $1.67B at that time.
Data tracked by StockTitan Argus on the day of publication.
In the episode titled "Don't Wait for the Wake-Up Call," Dr. Ding explains why early detection of diabetes is a clinical and economic priority. With diabetes affecting millions of people worldwide – many undiagnosed until complications arise – early testing offers a critical opportunity to shift care from reactive to proactive. Dr. Ding shares how modern laboratory platforms and emerging biomarkers are helping clinicians intervene sooner, personalize care and prevent long-term harm.
Key insights include:
- Early action saves lives: Detecting diabetes before complications occur changes the patient's health trajectory.
- Beyond glucose: Emerging biomarkers like C-peptide, pro-insulin and adiponectin offer a more complete metabolic picture.
- Smarter labs, faster answers: Automation-ready platforms deliver reliable results quickly, supporting timely clinical decisions.
- Economic impact: Early testing reduces costly interventions and aligns with value-based care models.
- Equity in care: Tailored testing strategies ensure accurate diagnosis across diverse populations.
This episode underscores how collaboration between labs and clinicians can help close the loop between diagnostics and care – empowering better outcomes and healthier futures.
The QuidelOrtho Science Bytes podcast is available on major streaming platforms and at: https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes.
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, delivering fast, accurate and reliable results that help improve patient outcomes – from the point of care to lab, clinic to hospital. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com
Media Contact:
D. Nikki Wheeler
Senior Director, Corporate Communications
Media@QuidelOrtho.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/the-power-of-prevention-detecting-diabetes-before-it-strikes-302621120.html
SOURCE QuidelOrtho Corporation
FAQ
What does QuidelOrtho (QDEL) discuss in the Nov 20, 2025 Science Bytes Episode 53?
Which biomarkers does QuidelOrtho highlight for early diabetes detection in Episode 53?
How does QuidelOrtho say lab automation affects diabetes diagnosis?
What patient‑care benefits does early diabetes testing offer according to the podcast?
Does QuidelOrtho address equity in diabetes testing in the podcast?
Where can investors and clinicians listen to QuidelOrtho Science Bytes Episode 53 (QDEL)?
